Medisprof S.R.L. — Clinical Trial Site

54 Registered trials

16 Currently recruiting

Organisation

Medisprof S.R.L.

Location

Cluj-Napoca, Romania

Identifier

ORG-100033873

Address

Bulevardul Muncii Nr. 283, 400641, Romania

Departments

3202: Oncology
3202:oncology
6102: Oncology
6109:Oncology
732: Oncology
93150002: Oncology
Departament Clinic Oncologie Medicala
Department of Medical Oncology
Medical Oncology
N/A
Oncologie
Oncologie medicala
Oncology
Oncology Department
ROU003: Oncology
Secţia Oncologie Medicală
Specialitatea Oncologie Generala si Chimioterapie

Clinical trials at this site (54)

Search interface

A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma… Ended

2023-503575-21-00 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser 5 2024-01-23
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin… Ended

2023-507522-16-00 Metastatic Esophageal or Gastric Cancer 5 2023-05-22
Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U… Ended

2023-505772-30-00 Melanoma 5 2022-11-09
Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended

2023-509429-37-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5 2022-10-03
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 PD-L1-negative metastatic triple-negative breast cancer 5 2022-08-31
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET Driven, Unresectable and Locally Advanced or Metastatic PRCC … Ended

2022-503105-38-00 MET-driven, unresectable and locally advanced or metast 5 2021-10-22
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas… Ended

2023-510319-20-00 Gastroesophageal Adenocarcinoma (GEA) 5 2021-10-21
A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended

2023-508723-12-00 gastroenteropancreatic neuroendocrine tumors 5 2021-09-27
Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A… Ended

2023-507963-20-00 Metastatic Gastric Adenocarcinoma 5 2021-08-19
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer 5 2018-11-27
Study of two different doses of cabozantinib in progressive, metastatic medullary thyroid cancer Ended

2024-516480-90-00 Metastatic Medullary Thyroid Cancer 6 2015-11-23
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastati… Ended

2023-506882-70-00 Non-small-cell lung cancer 5 2024-08-16
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE Ended

2022-502716-37-00 Recurrent or advanced/metastatic solid tumors who are i 4 2023-11-27
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended

2022-502476-23-00 Treatment of immunotherapy-naive patients with previous 4 2023-10-25
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Resected squamous cell carcinoma of the head and neck 5 2022-12-16
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J… Ended

2023-505457-40-00 Previously Untreated Advanced Gastric or Gastroesophage 5 2022-02-02
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Ended

2023-503280-42-00 Metastatic Clear Cell Renal Cell Carcinoma 5 2021-06-01